XYLOCAINE 2% W EPINEPHRINE 1:100000 LIQUID

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

LIDOCAINE HYDROCHLORIDE; EPINEPHRINE (EPINEPHRINE BITARTRATE)

Disponible depuis:

ASTRAZENECA CANADA INC

Code ATC:

N01BB52

DCI (Dénomination commune internationale):

LIDOCAINE, COMBINATIONS

Dosage:

20MG; 0.01MG

forme pharmaceutique:

LIQUID

Composition:

LIDOCAINE HYDROCHLORIDE 20MG; EPINEPHRINE (EPINEPHRINE BITARTRATE) 0.01MG

Mode d'administration:

BLOCK/INFILTRATION

Unités en paquet:

10X20ML,10X50ML

Type d'ordonnance:

Ethical

Domaine thérapeutique:

LOCAL ANESTHETICS

Descriptif du produit:

Active ingredient group (AIG) number: 0201284005; AHFS:

Statut de autorisation:

CANCELLED POST MARKET

Date de l'autorisation:

2012-09-12

Résumé des caractéristiques du produit

COPYRIGHT 1954, 2008 ASTRAZENECA CANADA INC.
Page 1 of 31
PRESCRIBING INFORMATION
XYLOCAINE
® PARENTERAL SOLUTIONS
Lidocaine Hydrochloride Injection USP
0.5%, 1%, and 2%
Lidocaine Hydrochloride and Epinephrine Injection USP
1%, 1.5% and 2%
(lidocaine hydrochloride with epinephrine 1:200,000 and 1:100,000)
Local Anesthetic
AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
L4Y 1M4
www.astrazeneca.ca
DATE OF REVISION:
SEPTEMBER 7, 2011
SUBMISSION CONTROL NO: 144224, 144225
XYLOCAINE
®
is a registered trademark of the AstraZeneca group of companies.
COPYRIGHT 1954, 2008 ASTRAZENECA CANADA INC.
Page 2 of 31
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................3
SUMMARY PRODUCT
INFORMATION......................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS.................................................................................................4
WARNINGS AND PRECAUTIONS
...............................................................................5
ADVERSE REACTIONS
...............................................................................................12
DRUG
INTERACTIONS................................................................................................14
DOSAGE AND ADMINISTRATION
...........................................................................16
OVERDOSAGE..............................................................................................................20
ACTION AND CLINICAL
PHARMACOLOGY..........................................................22
STORAGE AND STABILITY
.......................................................................................24
SPECIAL HANDLING
INSTRUCTIONS.....................................................................24
DOSAGE FORMS, COMPOSITION AND
PACKAGING...........................................25
PART II: SCIENTIFIC
INFORMA